Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2026, meaning its operating cash flow of $-172.75K could theoretically repay 0% of its total liabilities ($18.14 Million) in one year. See Drugs Made In America Acquisition II Cor leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Drugs Made In America Acquisition II Corp. Ordinary Shares across 2 annual periods. For the full cash flow conversion analysis, see DMII cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition II Corp. Ordinary Shares. Check Drugs Made In America Acquisition II Cor earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.06x | $-1.02 Million | $17.80 Million | ▲ +92.5% |
| 2024 | -0.76x | $-194.30K | $254.78K | — |